A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality
Ana Fernández‐Cruz, Belén Ruíz‐Antorán, Ana Muñoz‐Gómez, Aránzazu Sancho‐López, Patricia Mills-Sánchez, Gustavo Adolfo Centeno-Soto, Silvia Blanco‐Alonso, Laura Javaloyes-Garachana, Amy Galán Gómez, Ángela Valencia-Alijo, Javier Gómez-Irusta, Concepción Payares‐Herrera, Ignacio Morrás-Torre, Enrique Sánchez-Chica, Laura Delgado-Téllez-de-Cepeda, Alejandro Callejas‐Díaz, António Ramos, Elena Múñez, C. Avendaño
Abstract
Evidence to support the use of steroids in coronavirus disease 2019 (COVID-19) pneumonia is lacking. We aim to determine the impact of steroid use for COVID-19 pneumonia on hospital mortality. We performed a single-center retrospective cohort study in a university hospital in Madrid, Spain, during March of 2020. To determine the role of steroids in in-hospital mortality, patients admitted with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and treated with steroids were compared to patients not treated with steroids, and we adjusted with a propensity score for patients on steroid treatment.